DAVIS & HARMAN LLP for EMERGENT BIOSOLUTIONS, INC.
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 14, 2020 | — | Replaced |
| 4th Quarter - Termination (this page) | Sep 4, 2020 | — | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS A DAVIS | — |
| CHRIS L GASTON New | Chief of Staff, Rep. Rush Holt |
Budget/Appropriations BUD
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS A DAVIS | — |
| CHRIS L GASTON New | Chief of Staff, Rep. Rush Holt |
Homeland Security HOM
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (H.R. 269/S. 1379). NDAA - provisions related to biological and chemical defense. Department of Defense appropriations for Medical countermeasures. FDA regulatory issues. Issues related to Priority Review Voucher programs. Opioid and heroin legislation. Naloxone access, coprescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS A DAVIS | — |
| CHRIS L GASTON New | Chief of Staff, Rep. Rush Holt |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.